Cost-effectiveness analysis of additional local prostate radio therapy in metastatic prostate cancer from a medicare perspective
Additional RT is cost-effective in patients with only NRLN metastases and up to three metastases compared to SOC.
Authors
- Marco Foglar (ORCID: https://orcid.org/0000-0002-8597-9435)
- Nina-Sophie Schmidt-Hegemann (ORCID: https://orcid.org/0000-0002-2091-3603)
- C. Benedikt Westphalen (ORCID: https://orcid.org/0000-0002-5310-3754)
- Jens Ricke (ORCID: https://orcid.org/0000-0001-8762-8594)
- Marcus Unterrainer (ORCID: https://orcid.org/0000-0002-8238-1198)
- Wolfgang G. Kunz (ORCID: https://orcid.org/0000-0002-5021-1952)
- Kristina K. M. Kramer
- Thilo Westhofen (ORCID: https://orcid.org/0000-0003-3812-5485)
- Dirk Mehrens (ORCID: https://orcid.org/0000-0001-5114-8935)
Institutions
- LMU Klinikum (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Radiation Oncology
- Published
- 2024-11-21
- DOI
- https://doi.org/10.1186/s13014-024-02544-0
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- Ludwig-Maximilians-Universität München